1. Home
  2. NCRA vs ONCO Comparison

NCRA vs ONCO Comparison

Compare NCRA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.89

Market Cap

3.1M

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.61

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
ONCO
Founded
2002
2018
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
2.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NCRA
ONCO
Price
$1.89
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
305.3K
197.7K
Earning Date
04-15-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
$13,627,944.00
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.09
52 Week High
$3.98
$6.73

Technical Indicators

Market Signals
Indicator
NCRA
ONCO
Relative Strength Index (RSI) 50.15 35.45
Support Level $0.18 $0.60
Resistance Level $2.59 $1.01
Average True Range (ATR) 0.19 0.05
MACD -0.09 -0.01
Stochastic Oscillator 14.12 6.30

Price Performance

Historical Comparison
NCRA
ONCO

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: